(EVH) Evolent Health - Ratings and Ratios
Technology, Services, Care, Population, Management
EVH EPS (Earnings per Share)
EVH Revenue
Description: EVH Evolent Health
Evolent Health Inc (NYSE:EVH) is a US-based company operating in the Health Care Technology sub-industry. As a trading analyst, its crucial to understand the companys financials and market performance. The quarterly Tax Provision data suggests that the companys financials are being closely monitored.
To better understand EVHs position, we need to examine key performance indicators (KPIs) such as revenue growth, operating margins, and cash flow. Given the companys negative Return on Equity (RoE) of -16.70%, its likely that EVH is still in a growth phase, investing heavily in its business. The forward Price-to-Earnings (P/E) ratio of 90.09 indicates high growth expectations from investors.
The market capitalization of $1.043 billion USD and average trading volume of 2.1 million shares suggest a relatively liquid stock. However, the stocks beta of 0.815 indicates that its less volatile than the overall market, which might be attractive to risk-averse investors. Key economic drivers for EVH include the growing demand for healthcare technology, the shift towards value-based care, and the increasing adoption of digital health solutions.
To identify potential trading opportunities, its essential to analyze EVHs financial statements, management guidance, and industry trends. Some potential KPIs to monitor include revenue growth rate, operating expense ratio, and cash flow from operations. By deconstructing these fundamental drivers, we can better understand EVHs intrinsic value and identify potential entry and exit points for trades.
EVH Stock Overview
| Market Cap in USD | 1,044m |
| Sub-Industry | Health Care Technology |
| IPO / Inception | 2015-06-05 |
EVH Stock Ratings
| Growth Rating | -48.0% |
| Fundamental | 34.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -74.1% |
| Analyst Rating | 4.57 of 5 |
EVH Dividends
Currently no dividends paidEVH Growth Ratios
| Growth Correlation 3m | 12.8% |
| Growth Correlation 12m | -76.7% |
| Growth Correlation 5y | -11.3% |
| CAGR 5y | -7.63% |
| CAGR/Max DD 5y | -0.09 |
| Sharpe Ratio 12m | -0.43 |
| Alpha | -59.94 |
| Beta | -1.016 |
| Volatility | 55.52% |
| Current Volume | 1367.2k |
| Average Volume 20d | 2236.5k |
| Stop Loss | 8.9 (-7.8%) |
| Signal | -0.30 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-161.6m TTM) > 0 and > 6% of Revenue (6% = 131.8m TTM) |
| FCFTA -0.00 (>2.0%) and ΔFCFTA -6.35pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 0.22% (prev 1.60%; Δ -1.38pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.01 (>3.0%) and CFO -33.3m > Net Income -161.6m (YES >=105%, WARN >=100%) |
| Net Debt (53.7m) to EBITDA (10.6m) ratio: 5.09 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.01 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (115.9m) change vs 12m ago 1.04% (target <= -2.0% for YES) |
| Gross Margin 16.36% (prev 16.03%; Δ 0.33pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 88.96% (prev 95.10%; Δ -6.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.79 (EBITDA TTM 10.6m / Interest Expense TTM 34.7m) >= 6 (WARN >= 3) |
Altman Z'' -1.90
| (A) 0.00 = (Total Current Assets 562.3m - Total Current Liabilities 557.5m) / Total Assets 2.46b |
| (B) -0.35 = Retained Earnings (Balance) -865.3m / Total Assets 2.46b |
| (C) -0.04 = EBIT TTM -96.8m / Avg Total Assets 2.47b |
| (D) -0.48 = Book Value of Equity -638.2m / Total Liabilities 1.34b |
| Total Rating: -1.90 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 34.04
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -0.35% = -0.18 |
| 3. FCF Margin -0.28% = -0.10 |
| 4. Debt/Equity 0.94 = 2.07 |
| 5. Debt/Ebitda 80.02 = -2.50 |
| 6. ROIC - WACC -7.46% = -9.32 |
| 7. RoE -16.70% = -2.50 |
| 8. Rev. Trend 58.65% = 2.93 |
| 9. Rev. CAGR 8.77% = 1.10 |
| 10. EPS Trend -58.32% = -1.46 |
| 11. EPS CAGR -210.9% = -2.50 |
What is the price of EVH shares?
Over the past week, the price has changed by +0.52%, over one month by +2.55%, over three months by +30.94% and over the past year by -69.71%.
Is Evolent Health a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EVH is around 8.11 USD . This means that EVH is currently overvalued and has a potential downside of -15.96%.
Is EVH a buy, sell or hold?
- Strong Buy: 9
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the EVH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.3 | 58.7% |
| Analysts Target Price | 15.1 | 56.3% |
| ValueRay Target Price | 8.6 | -11.4% |
Last update: 2025-08-21 02:49
EVH Fundamental Data Overview
CCE Cash And Equivalents = 151.0m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 90.0901
P/S = 0.4753
P/B = 1.1649
P/EG = -1.37
Beta = 0.815
Revenue TTM = 2.20b USD
EBIT TTM = -96.8m USD
EBITDA TTM = 10.6m USD
Long Term Debt = 648.5m USD (from longTermDebt, last quarter)
Short Term Debt = 196.3m USD (from shortTermDebt, last quarter)
Debt = 844.8m USD (Calculated: Short Term 196.3m + Long Term 648.5m)
Net Debt = 53.7m USD (from netDebt column, last quarter)
Enterprise Value = 1.74b USD (1.04b + Debt 844.8m - CCE 151.0m)
Interest Coverage Ratio = -2.79 (Ebit TTM -96.8m / Interest Expense TTM 34.7m)
FCF Yield = -0.35% (FCF TTM -6.13m / Enterprise Value 1.74b)
FCF Margin = -0.28% (FCF TTM -6.13m / Revenue TTM 2.20b)
Net Margin = -7.36% (Net Income TTM -161.6m / Revenue TTM 2.20b)
Gross Margin = 16.36% ((Revenue TTM 2.20b - Cost of Revenue TTM 1.84b) / Revenue TTM)
Tobins Q-Ratio = -2.72 (set to none) (Enterprise Value 1.74b / Book Value Of Equity -638.2m)
Interest Expense / Debt = 1.37% (Interest Expense 11.6m / Debt 844.8m)
Taxrate = 21.0% (US default)
NOPAT = -96.8m (EBIT -96.8m, no tax applied on loss)
Current Ratio = 1.01 (Total Current Assets 562.3m / Total Current Liabilities 557.5m)
Debt / Equity = 0.94 (Debt 844.8m / last Quarter total Stockholder Equity 896.0m)
Debt / EBITDA = 80.02 (Net Debt 53.7m / EBITDA 10.6m)
Debt / FCF = -137.9 (Debt 844.8m / FCF TTM -6.13m)
Total Stockholder Equity = 967.9m (last 4 quarters mean)
RoA = -6.57% (Net Income -161.6m, Total Assets 2.46b )
RoE = -16.70% (Net Income TTM -161.6m / Total Stockholder Equity 967.9m)
RoCE = -5.99% (Ebit -96.8m / (Equity 967.9m + L.T.Debt 648.5m))
RoIC = -5.72% (NOPAT -96.8m / Invested Capital 1.69b)
WACC = 1.74% (E(1.04b)/V(1.89b) * Re(2.27%)) + (D(844.8m)/V(1.89b) * Rd(1.37%) * (1-Tc(0.21)))
Shares Correlation 5-Years: 100.0 | Cagr: 7.02%
Discount Rate = 2.27% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -6.13m)
Revenue Correlation: 58.65 | Revenue CAGR: 8.77%
Rev Growth-of-Growth: -44.16
EPS Correlation: -58.32 | EPS CAGR: -210.9%
EPS Growth-of-Growth: -12.60
Additional Sources for EVH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle